Navigation Links
Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset

DEERFIELD, Ill., Oct. 10 /PRNewswire/ -- Astellas Pharma US, Inc. today announced that the investigational agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or SR) in patients with atrial fibrillation (AF) treated within 48 hours of the onset of symptoms. AF is a serious condition characterized by an irregular heart rhythm and a high heart rate, and frequently leads to emergency department visits. The study results were presented during the annual meeting of the American College of Emergency Physicians in Seattle.

"Most patients who develop symptoms of AF come to the emergency department within the first 48 hours," said Ian Stiell, MD of the University of Ottawa, Canada. "This analysis shows that vernakalant may provide emergency medicine physicians with an effective treatment option for managing acute AF."

AF is the most common cardiac arrhythmia, which leads to approximately 15 percent of all strokes.(1) The number of AF patients is expected to triple over the next 50 years due to the increased prevalence of risk factors including hypertension, obesity, diastolic dysfunction, inflammation, diabetes and sleep apnea.(2)

Study Results

The study, referred to as the atrial arrhythmia conversion trial or ACT I, was a prospective, randomized, double-blind, placebo-controlled trial of patients with symptomatic AF or nontypical atrial flutter, conducted at 44 sites in Canada, the United States, Denmark, and Sweden. This study assessed the efficacy and safety of vernakalant in converting AF lasting 3 h to <45 d to SR. The current findings are based on a sub-analysis in patients with acute AF lasting 3 to 48 h.

A total of 161 of 356 patients (45 percent) in ACT I presented within 48 hours of AF onset. Of these, 102 patients (63 percent) received vernakalant and 59 patients (37 percent) received placebo.

Patients with AF were randomly assigned in a 2:1 ratio to vernakalant 3 mg/kg or placebo infused over 10 minutes. After 15 minutes, a second 10 minute infusion of vernakalant 2 mg/kg or placebo was given if AF persisted or atrial flutter was present. The primary efficacy measure was the percentage of patients demonstrating conversion to SR for at least one minute within 90 minutes of dosing. Patients demonstrating conversion within 90 minutes were categorized as responders. Other efficacy measures included median time to conversion and the percentage of patients still in sinus rhythm at hour 24 and day 7.

In this subanalysis, a significantly higher percentage of patients with acute AF given vernakalant (61.8 percent) demonstrated conversion to SR within 90 minutes compared to patients given placebo (5.1 percent), P<.0001. Conversion from AF to SR with vernakalant was rapid and sustained. Among vernakalant responders, median conversion time was 11 minutes, and SR was maintained for 24 h in 97 percent and for 7 days in 93 percent. Seventy-eight percent of vernakalant responders required only one dose of the drug.

The most common adverse events (AEs) in patients given vernakalant were taste disturbance (32.4 percent), sneezing (16.7 percent), nausea (15.7 percent) and dizziness (11.8 percent). The incidence of serious AEs was similar in the vernakalant and placebo treatment groups for both the entire period and the first 24 hours (11.8 percent vs. 15.3 percent and 3.9 percent vs. 1.7 percent, respectively).

About Atrial Fibrillation

Atrial fibrillation (AF) is an interruption of the normal sinus rhythm (arrhythmia) of the heart in which the atria, the two uppermost chambers of the heart, beat irregularly and at an extremely rapid rate.(1) During AF, rapid and uncoordinated electrical discharges are generated by the heart's natural pacemaker (sinoatrial node) and other parts of the atria. This causes ineffective contractions of the atria and reduces the ability of the heart to pump blood through the body. Symptoms include dizziness, heart palpitations, weakness, shortness of breath and angina (chest pain).(3)

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the US, Astellas markets products in the areas of Immunology, Urology, Anti-Infectives, Cardiovascular and Dermatology. For more information about Astellas Pharma US, Inc., please visit our website at


(1) Arrhythmias Originating in the Atria. American Heart Association: Accessed

July 10, 2007.

(2) Miyasaka Y, Barnes ME, Gersh BJ, et al. American Heart Association:

Accessed June 28, 2007.

(3) Mayo Clinic. Atrial fibrillation. Available at: Accessed

October 26, 2006.

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Lexicon Pharmaceuticals, Inc. ... top-line data from its TELECAST Phase 3 ... treating carcinoid syndrome in cancer patients with ... benefit observed in its pivotal TELESTAR study.  ... companion to TELESTAR primarily to provide additional ...
(Date:12/1/2015)... , Dec. 1, 2015  ImmunoCellular Therapeutics, ... Andrew Gengos , President and Chief ... on December 3, 2015. Mr. Gengos plans ... registrational program in patients with newly diagnosed ... TIME:    12:15p.m. ET/9:15a.m. PT LINK: ...
(Date:12/1/2015)... and UPPSALA, Sweden , December ... been selected by the International Breast Cancer Study Group (IBCSG, ... (BIG, Brussels ) to be part of ... palbociclib, a promising new cancer drug.  --> ... women with advanced breast cancer being treated with anti-hormonal therapy ...
Breaking Medicine Technology:
(Date:12/1/2015)... PA (PRWEB) , ... December 01, 2015 , ... ... imaging facilities, radiographic technicians must mark the film for accurate interpretation by the ... track of. Fortunately, an inventor from Sacramento, Calif., has found a way to ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... honors Christina Colon as a 2015-2016 inductee into its VIP Woman ... in pharmacy. NAPW is the nation’s leading networking organization exclusively for professional women, ...
Breaking Medicine News(10 mins):